BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Small Cap Pro

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years $2158.56 only $755.50

ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,998.74
      -0.38%
      US Tech 100
      20,208.80
      -0.80%
      Dow Jones
      44,722.06
      -0.31%
      Brent Oil
      72.375
      -0.10%
      Bitcoin
      96,588.00
      5.02%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Zentalis Pharmaceuticals Inc (ZNTL)

      7. Zentalis Pharmaceuticals Inc (ZNTL) News

      Zentalis Pharmaceuticals Inc

      Zentalis Pharmaceuticals Inc (ZNTL)

      NASDAQ
      3.63
      0.15
      (4.31%)
      At close: November 27 4:00PM
      Delayed by 15 minutes
      3.63
      0.00
      ( 0.00% )
      After Hours: 4:30PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      ZNTL News

      Official News Only

      Form 3 - Initial statement of beneficial ownership of securities
      Edgar (US Regulatory)
      November 13 2024
      ZNTL (4.31%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 13 2024
      ZNTL (4.31%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      October 04 2024
      ZNTL (4.31%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      September 16 2024
      ZNTL (4.31%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      August 09 2024
      ZNTL (4.31%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      August 09 2024
      ZNTL (4.31%)

      ZNTL Discussion

      View Posts
      Awl416 Awl416 2 months ago
      Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
      👍️0
      glenn1919 glenn1919 2 months ago
      ZNTL.......................................https://stockcharts.com/h-sc/ui?s=ZNTL&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 3 months ago
      ZNTL under $4
      👍️0
      ANTADOG ANTADOG 4 years ago
      We managed to get a new 26 week high and a reset around 46 bucks, will be interesting to see where it goes next, chartwise it's up, imo of course, ANT
      👍️0
      ANTADOG ANTADOG 4 years ago
      Added some 46's , nice chart reset, ANT
      👍️0
      ANTADOG ANTADOG 4 years ago
      55.12~~ looks like this puppy is on it's way for a new 52 week high, my target here is 100 bucks because of the very promising pipeline , fyi imo ANT
      👍️0
      ANTADOG ANTADOG 4 years ago
      NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Ahmed Samatar, Ph.D., Senior Vice President of Oncology Research at Zentalis, will present preclinical data on ZN-c5 at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting II taking place June 22-24th.

      The preclinical data demonstrated that ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, had antitumor activity in human tumor breast cancer xenograft models. ZN-c5 also displayed excellent oral bioavailability across several preclinical species. ZN-c5 is currently being evaluated in a Phase 1/2 clinical trial in patients with ER+/HER2- advanced or metastatic breast cancer both as a single agent and in combination studies.
      👍️0
      ANTADOG ANTADOG 4 years ago
      NEW YORK and SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.
      fyi ANT
      👍️0
      ANTADOG ANTADOG 4 years ago
      New 52 week high at 52.09, i luv it, ANT
      👍️0
      ANTADOG ANTADOG 5 years ago
      Cash Position: As of March 31, 2020, Zentalis had cash and cash equivalents of $63.7 million. We expect that the Company’s existing cash and cash equivalents, together with the net proceeds of $172.4 million from the IPO, will enable the Company to fund its operating expenses and capital expenditure requirements into 2022.
      fyi ANT
      👍️0
      ANTADOG ANTADOG 5 years ago
      Chart is pretty fresh here, anyway, i see a trendline curlin' up already (10ma on the daily at 35.9), fyi ANT
      👍️0
      ANTADOG ANTADOG 5 years ago
      promisin' co, interestin' pipeline, touched new 52 week high today (42.83), enormous spread every now and then, fyi ANT
      👍️0
      crudeoil24 crudeoil24 5 years ago
      ZNTL opens @ 25.20 >
      👍️0
      crudeoil24 crudeoil24 5 years ago
      Zentalis Pharma Upsized IPO Prices at High End of Range >ZNTL
      6:08 am ET April 3, 2020 (Dow Jones) Print
      By Colin Kellaher

      Zentalis Pharmaceuticals Inc. said its upsized initial public offering of 9.18 million shares was priced at $18 each, the high end of the expected range.

      The New York clinical-stage cancer biopharmaceutical company earlier this week said it expected to sell 7.65 million shares at $16 to $18 apiece.

      Zentalis said it expects gross proceeds of $165.2 million from the IPO, adding that it has granted the underwriters an option to buy up to 1.38 million additional shares.

      Zentalis previously said it will use proceeds from the offering to advance the development of its drug candidates.

      Write to Colin Kellaher at colin.kellaher@wsj.com

      (END) Dow Jones Newswires

      April 03, 2020 06:08 ET (10:08 GMT)

      Copyright (c) 2020 Dow Jones & Company, Inc.
      👍️0
      crudeoil24 crudeoil24 5 years ago
      Zentalis Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
      👍️0

      Your Recent History

      NASDAQ
      ZNTL
      Zentalis Pharmaceuticals
      Delayed Upgrade Clock